Summary
No auditable comparison to the supplied FDA label excerpts is possible because the AI-generated response text was provided only as a list of claims without the actual FDA label content for most required sections (e.g., indication, dosage/administration, contraindications, drug interactions, use in specific populations, administration/storage). Only Warnings/Precautions sections 5.4 and 5.5 and limited drug interaction pharmacokinetics text were provided, so most claims cannot be validated.
Category Scores
Accurate Statements
LYRICA may cause dizziness and somnolence and dizziness/somnolence generally occurred more frequently at higher doses (label: “occurred more frequently at higher doses”).
Label excerpt 5.5: “Dizziness and somnolence generally began shortly after the initiation of LYRICA therapy and occurred more frequently at higher doses.”
Breathing suppression/respiratory depression is a serious potential complication when LYRICA is co-administered with CNS depressants (including opioids) or in underlying respiratory impairment; monitor for respiratory depression and sedation; consider initiating at low dose; management may include supportive measures and reduction/withdrawal of CNS depressants (including LYRICA).
Label excerpt 5.4 Respiratory Depression: “associating LYRICA with serious, life-threatening, or fatal respiratory depression when co-administered with CNS depressants, including opioids, or in the setting of underlying respiratory impairment… monitor… consider initiating… low dose… management… close observation… supportive measures, and reduction or withdrawal of CNS depressants (including LYRICA).”
Unsupported Statements
Alcohol can increase sedation and impair coordination.
Not supported by the supplied label excerpts. Only LYRICA dizziness/somnolence and respiratory depression with CNS depressants/underlying respiratory impairment are provided; alcohol-specific statements are not included in the excerpts.
Combining alcohol and pregabalin raises the risk of falls, accidents, and dangerous impairment.
Falls/accidents/impairment outcomes in the context of alcohol are not present in the supplied excerpts.
The risk is especially increased at higher pregabalin doses.
The label excerpt 5.5 supports that dizziness/somnolence occurred more frequently at higher doses, but the broader 'risk' framing across alcohol combination and falls/accidents is not supported by the provided text.
The effect of combining alcohol and pregabalin is often dose-related.
Dose-related effects of the alcohol + pregabalin combination are not described in the supplied excerpts.
Higher pregabalin exposure typically produces more drowsiness and dizziness.
Generally consistent with label 5.5 for dizziness/somnolence, but the 'typically produces' phrasing as a direct consequence is not fully auditable for alcohol-combination claims; evaluated as unsupported for the alcohol combination context.
Alcohol and pregabalin can cause additive central nervous system depression.
The supplied excerpt 5.4 supports respiratory depression with CNS depressants, and 5.5 supports dizziness/somnolence with LYRICA, but it does not explicitly state alcohol-specific 'additive CNS depression.'
Additive central nervous system depression can make people feel overly sleepy, lightheaded, or unsteady.
The supplied excerpts do not include these specific symptom groupings (lightheaded/unsteady) as an alcohol + pregabalin combination effect.
Alcohol and pregabalin can increase the likelihood of falls.
Falls risk is not addressed in the provided excerpts.
Alcohol and pregabalin can increase motor-vehicle risk.
The supplied excerpts mention tasks such as driving/operating machinery may be impaired by LYRICA-related dizziness/somnolence, but do not support alcohol-specific motor-vehicle risk.
Breathing suppression is a more serious concern when taking alcohol with pregabalin.
Label excerpt 5.4 discusses CNS depressants (including opioids) and underlying respiratory impairment; alcohol-specific respiratory depression framing is not provided.
Breathing suppression is more likely when someone takes multiple substances that depress breathing or when pregabalin exposure is high.
The supplied excerpt 5.4 supports risk with CNS depressants (including opioids) and underlying respiratory impairment, but does not state 'when pregabalin exposure is high' for respiratory depression.
The risk of breathing suppression is higher in people with opioid use or existing breathing conditions.
Partially consistent with 'including opioids' and 'underlying respiratory impairment,' but 'higher risk' phrasing tied to opioid use/existing breathing conditions is not quantitatively or explicitly stated beyond association; additionally, opioid exposure vs underlying impairment is not detailed in the excerpt.
Alcohol can still make impairment worse.
Not explicitly supported in the provided label excerpts.
Higher pregabalin doses tend to carry higher rates of sedation and dizziness.
Label 5.5 supports dizziness/somnolence more frequently at higher doses, but it does not quantify 'rates of sedation' in the alcohol combination context.
Combining alcohol with higher pregabalin doses is generally more risky.
The label excerpt does not describe alcohol combination risk increasing with pregabalin dose.
The exact threshold where risk increases varies by person.
No threshold variability statement is included in supplied excerpts.
Alcohol sensitivity, body weight, liver function, and other medications affect outcomes.
Not supported by the supplied excerpts.
Sleepiness and coordination problems from pregabalin increase with dose.
Label 5.5 supports dizziness and somnolence occur more frequently at higher doses; 'coordination problems' are not explicitly stated in the excerpt.
Alcohol adds to pregabalin-related sedation.
Not explicitly supported for alcohol in the supplied excerpts.
Common immediate issues from drinking while taking Lyrica include increased drowsiness.
Label excerpt 5.5 supports LYRICA-related somnolence/dizziness, but does not specify drinking while taking LYRICA.
Common immediate issues from drinking while taking Lyrica include dizziness.
Same limitation: label excerpt 5.5 discusses LYRICA dizziness vs placebo; not 'drinking while taking.'
Common immediate issues from drinking while taking Lyrica include slower reaction time.
Slower reaction time is not stated in the supplied excerpts.
Increased drowsiness, dizziness, and slower reaction time can lead to trouble driving or operating machinery.
Label excerpt supports dizziness/somnolence may impair ability to perform tasks such as driving/operating machinery, but 'slower reaction time' is not supported.
Increased drowsiness, dizziness, and slower reaction time can lead to falls or loss of balance.
Falls/loss of balance are not supported in the supplied excerpts.
Increased drowsiness, dizziness, and slower reaction time can make it more difficult to judge how impaired a person is.
Not supported in the supplied excerpts.
Feeling unusually sleepy, confused, or having trouble staying awake can be a warning sign that the combination is overwhelming the system.
Not supported as a label statement in the supplied excerpts.
Avoiding alcohol is especially important if the patient takes other medications that also cause sedation, such as opioids, benzodiazepines, or other sleep-inducing drugs.
The supplied excerpt 5.4 discusses CNS depressants including opioids and monitoring/starting low dose; it does not explicitly mention alcohol avoidance, benzodiazepines, or 'sleep-inducing drugs.'
People with lung or breathing problems should be cautious with alcohol and Lyrica.
Label excerpt 5.4 discusses underlying respiratory impairment and monitoring; it does not explicitly mention alcohol or a caution statement combining alcohol with such patient groups.
Depressed breathing is a more serious potential complication for people with lung or breathing problems.
This is consistent directionally with 'underlying respiratory impairment' but the exact phrasing 'more serious potential complication for lung/breathing problems' is not explicitly stated in the supplied excerpts.
If someone becomes very drowsy, difficult to wake, confused, has slow or shallow breathing, or cannot stay upright, it should be treated as urgent.
Not supported in the supplied excerpts; the excerpt 5.4 provides monitoring/management concepts but does not provide this specific symptom-to-urgency instruction.
In the U.S., calling Poison Control (1-800-222-1222) or seeking emergency care is appropriate when symptoms suggest severe sedation or breathing risk.
Not present in the supplied label excerpts.
Contradictions
Low
AI Statement
The provided evaluation that the claim text was 'absent from the label' and therefore cannot be audited, while simultaneously asserting detailed label support is not internally consistent with the provided excerpts.
Label Reference
Not applicable—this is about the audit feasibility, not pregabalin-alcohol content.
Important Omissions
The user did not provide the actual FDA label sections needed to evaluate many claims (e.g., complete Contraindications, Boxed Warning, Drug Interactions specific to alcohol/ethanol, Dosage/Administration, and full Patient Counseling statements).
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Several claims are not supported by the supplied label excerpts (notably alcohol-specific fall/motor-vehicle/urgency/Poison Control guidance). Only general LYRICA dizziness/somnolence and respiratory depression with CNS depressants/underlying respiratory impairment are supported by the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Auditable Against Supplied Label
Primary Issue
Most claims involve alcohol-specific effects and detailed symptom/urgency guidance that are not present in the provided label excerpts; key label sections are missing.
Suggested Improvement
Provide the exact AI-generated response text as a single block and supply the corresponding full FDA label sections (at minimum: Indications, Dosage/Administration, Contraindications/Boxed Warning, full Warnings/Precautions including any alcohol-related counseling, Drug Interactions, and Patient Counseling/Medication Guide). Then re-run the claim-by-claim audit limited to those sections.